The role of F-18-FDG PET/CT in the assessment of suspected recurrent gastric cancer after initial surgical resection: can the results of FDG PET/CT influence patients' treatment decision making?

BILICI A., USTAALIOGLU B. B. O. , SEKER M., KEFELI U., CANPOLAT N., TEKINSOY B., OZUGUR S., Gumus M.

doi:10.1007/s00259-010-1611-1

The role of F-18-FDG PET/CT in the assessment of suspected recurrent gastric cancer after initial surgical resection: can the results of FDG PET/CT influence patients' treatment decision making?

BILICI A., USTAALIOGLU B. B. O. , SEKER M., KEFELI U., CANPOLAT N., TEKINSOY B., et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, cilt.38, ss.64-73, 2011

Cilt numarası: 38 Konu: 1
Basım Tarihi: 2011
Doi Numarası: 10.1007/s00259-010-1611-1
Dergi Adı: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Sayfa Sayısı: ss.64-73

Özet

F-18-fluorodeoxyglucose (FDG) PET/CT has been widely used for staging, re-staging and for monitoring therapy-induced changes and response to therapy in patients with various types of cancer, but its utilization for gastric cancer has been limited. The purpose of this study was to evaluate the clinical role of FDG PET/CT in the detection of gastric cancer recurrence as compared with diagnostic CT and to assess the impact of FDG PET/CT results on patients' treatment planning.